In successful melanoma immunotherapy, clonal TCRs can recognize multiple tumor-specific antigens simultaneously through cross-reactivity.
No takes yet. Share an insight, caveat, or question.
Asha Pillai (2023) studied this question.
Synapse has enriched one closely related paper. Consider it for comparative context: